Get the Stockscreener App
0.813
17.34%
-0.1706
After Hours:
.81
-0.003
-0.37%
Shattuck Labs Inc stock is traded at $0.813, with a volume of 97,539.
It is down -17.34% in the last 24 hours and down -33.36% over the past month.
See More
Previous Close:
$0.9836
Open:
$0.9305
24h Volume:
97,539
Relative Volume:
0.64
Market Cap:
$38.94M
Revenue:
$2.72M
Net Income/Loss:
$-85.08M
P/E Ratio:
-0.4212
EPS:
-1.93
Net Cash Flow:
$-70.93M
1W Performance:
-28.68%
1M Performance:
-33.36%
6M Performance:
-36.48%
1Y Performance:
-90.74%
1-Day Range:
$0.81
$0.9305
1-Week Range:
$0.81
$1.18
52-Week Range:
$0.81
$11.76
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
0.813 | 38.94M | 2.72M | -85.08M | -70.93M | -1.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference - TradingView
24,446 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Virtu Financial LLC - Defense World
STTK stock plunges to 52-week low, touches $0.93 - Investing.com
Brokers Issue Forecasts for Shattuck Labs Q1 Earnings - Defense World
515,619 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Takeda Pharmaceutical Co. Ltd. - MarketBeat
H.C. Wainwright holds Shattuck Labs stock at Neutral - Investing.com
Shattuck Labs Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Shattuck Labs (NASDAQ:STTK) Given Neutral Rating at HC Wainwright - Defense World
Shattuck Labs’ (STTK) “Hold” Rating Reaffirmed at Needham & Company LLC - Defense World
Shattuck Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Shattuck Labs Inc (STTK) Q4 2024 Earnings: EPS of -$0.37 Misses Estimate, Revenue of $0.71M Below Expectations - GuruFocus
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Shattuck Labs, Inc Loss At -$18.68 Mln In Q4 - Nasdaq
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of STTK, TLS and ASTR - ACCESS Newswire
Leerink Partnrs Forecasts Shattuck Labs FY2024 Earnings - Defense World
Brokerages Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $7.50 - Defense World
Shattuck Labs (NASDAQ:STTK) Upgraded at Leerink Partnrs - Defense World
Shattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform Recommendation - Nasdaq
Leerink initiates Shattuck Labs stock with Outperform, $4 target By Investing.com - Investing.com Canada
Leerink Partners Initiates Shattuck Labs at Outperform With $4 Price Target -March 17, 2025 at 07:39 am EDT - MarketScreener
Stocks Recover Some of This Week’s Losses as US Shutdown Seems Averted - TradingView
Stocks Rally as US Government Shutdown Risks Recede - TradingView
Tariff Worries Pressure Stocks - TradingView
Tariff Worries Sink Stocks - TradingView
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of STTK, RIVN and FB - ACCESS Newswire
Shattuck Labs Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Shattuck Labs (STTK) to Release Earnings on Thursday - Defense World
CLVT, SLI & STTK: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Upcoming Class Actions Deadlines and Encourages Shareholders to Contact the Firm - ACCESS Newswire
Shattuck Labs (STTK) Projected to Post Earnings on Wednesday - MarketBeat
Shattuck Labs reports positive preclinical SL-325 data By Investing.com - Investing.com Nigeria
Shattuck Labs reports positive preclinical SL-325 data - Investing.com
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 - The Manila Times
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at ... - The Bakersfield Californian
Breakthrough in IBD Treatment? Shattuck's Novel DR3 Blocker Achieves Perfect Safety Score - StockTitan
Shattuck Labs (STTK) Expected to Announce Earnings on Wednesday - Defense World
GoHealth to Announce Fourth Quarter 2024 Results on February 27, 2025 - The Manila Times
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 - The Manila Times
Revolutionary IBD Drug Development: Shattuck Labs Unveils Critical DR3 Antibody Results at ECCO 2025 - StockTitan
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights - br.ADVFN.com
Anti-DR3 antibody demonstrates efficacy in the treatment of IBD - BioWorld Online
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress - The Manila Times
Skye Bioscience Announces Participation in February Conferences - The Manila Times
Shattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis Congress - Nasdaq
Pivotal IBD Drug Development: Shattuck Labs Reveals SL-325 Data at Major Crohn's Congress - StockTitan
JPMorgan Chase & Co. Grows Position in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Natera Announces National Commercial Coverage for its Fetal RhD NIPT - BioSpace
Planet Image International Leads 3 US Penny Stocks To Consider - Simply Wall St
Cresco Labs (OTCMKTS:CRLBF) Trading 2.1% Higher – What’s Next? - Defense World
Vizient Forecasts a 3.84% Rise in Pharmacy Spending - BioSpace
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):